ChemicalBook >> CAS DataBase List >>BENZIMIDAVIR

BENZIMIDAVIR

BENZIMIDAVIR structure

CAS No.: 176161-24-3

Chemical Name:: BENZIMIDAVIR

Synonyms: Maribavir;1263W94;Maribavi;Malibawei;Malibave.;GW 257406X;BW 1263W94;BENZIMIDAVIR;Maribavir Impurity Crystal-Free Type VI;5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE

CBNumber:: CB6375292

Molecular Formula:: C15H19Cl2N3O4

Molecular Weight:: 376.24

MDL Number:: MFCD00945570

MOL File:: 176161-24-3.mol

MSDS File:: SDS

Last updated:2024-11-19 23:02:33

Request For Quotation

BENZIMIDAVIR Properties

Boiling point	611.0±65.0 °C(Predicted)
Density	1.67±0.1 g/cm3 (20 ºC 760 Torr)
storage temp.	2-8°C(protect from light)
solubility	Soluble in DMSO
form	Powder
pka	13.20±0.70(Predicted)
color	White to off-white
NCI Dictionary of Cancer Terms	maribavir
FDA UNII	PTB4X93HE1
ATC code	J05AX10

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H302
Precautionary statements	P264-P270-P301+P312-P501

BENZIMIDAVIR price

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	SML2941	Maribavir ≥98% (HPLC)	176161-24-3	5MG	$118	2024-03-01	Buy
Sigma-Aldrich	SML2941	Maribavir ≥98% (HPLC)	176161-24-3	25MG	$476	2024-03-01	Buy
ApexBio Technology	B3517	Maribavir	176161-24-3	10mg	$551	2021-12-16	Buy
American Custom Chemicals Corporation	API0004838	MARIBAVIR 95.00%	176161-24-3	5MG	$660	2021-12-16	Buy
ApexBio Technology	B3517	Maribavir	176161-24-3	5mg	$347	2021-12-16	Buy

Product number	Packaging	Price	Buy
SML2941	5MG	$118	Buy
SML2941	25MG	$476	Buy
B3517	10mg	$551	Buy
API0004838	5MG	$660	Buy
B3517	5mg	$347	Buy

BENZIMIDAVIR Chemical Properties,Uses,Production

Description

Maribavir is an orally bioavailable benzimidazole L-riboside antiviral, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein–Barr virus (EBV). It is an inhibitor of the CMV UL97 kinase. As of 2008, maribavir was in phase III clinical trials for prevention of CMV infection in transplant recipients at risk. Earlier phase I and II trials of maribavir showed anti-CMV activity with an acceptable adverse effect profile. Investigational drug code names include 1263W94, BW1263-W94, GW257406X, and VP41263, reflecting changes in ownership during drug development. As of early 2009, the drug was being developed under ‘‘fast track’’ status granted by the US Food and Drug Administration, but the apparent failure of maribar prophylaxis to prevent CMV infection in stem cell transplant recipients in the definitive phase III clinical trial resulted in the sponsor halting ongoing clinical development.

Uses

Treatment of cytomegalovirus infections (antiviral).

Mechanism of action

Maribavir inhibits the CMV UL97 kinase, an enzyme which is required for the normal replication of the virus . In the absence of functioning UL97 kinase, viral replication is severely impaired in vitro, with an abnormal cell culture cytopathic effect characterized by the nuclear aggregation of excess amorphous viral proteins, mainly the tegument protein pp65. Impaired UL97 function appears to cause a defect in viral encapsidation and/or egress of viral particles from the nucleus. In addition, viral DNA synthesis may also be reduced. CMV replication is not completely shut off in the absence of the UL97 kinase; the widely varying maribavir IC50s under different assay conditions suggest that host cells can variably substitute for the normal function of UL97, a factor that may affect the therapeutic potency of maribavir in vivo.

Drug interactions

Since CYP3A4 appears to be the major maribavir-metabolizing enzyme, there are potential drug interactions with CYP3A4 inhibitors, such as azole antifungals, macrolide antibiotics, and HIV protease inhibitors, or CYP3A4 inducers, such as rifampicin or efavirenz. There are insufficient data to assess the clinical significance of this interaction. Phase I clinical trials examined the pharmacokinetics of maribavir in HIV-infected subjects, many of whom were concomitantly using antifungals and protease inhibitors. Overall, the pharmacokinetic data were not significantly different from those of healthy individuals not on these drugs. In healthy adults, oral administration of ketoconazole, a potent CYP3A4 inhibitor, resulted in a 35% decrease in the clearance of maribavir, which is not expected to have adverse consequences because of the low observed toxicity of maribavir. Further studies are required to assess potential impairment of antiviral activity by CYP3A4 inducers. Maribavir may have some inhibitory effect on cytochrome P450 isozymes, CYP2C19 and CYP2D6, as assessed after administration of multiple concurrently administered drug probes, including omeprazole (2C19) and dextromethorphan (2D6).

BENZIMIDAVIR Preparation Products And Raw materials

Raw materials

Preparation Products

BENZIMIDAVIR Suppliers

Global( 156)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32956	60
Jinan Carbotang Biotech Co.,Ltd.	+8615866703830	figo.gao@foxmail.com	China	8497	58
Alchem Pharmtech,Inc.	8485655694	sales@alchempharmtech.com	United States	63687	58
Zhengzhou Alfa Chemical Co.,Ltd	+8618530059196	sale04@alfachem.cn	China	11705	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
Shanghai UCHEM Inc.	+862156762820 +86-13564624040	sales@myuchem.com	China	7688	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10473	58
NewCan Biotech Limited	+86-0571-86912261 +8613735419629	sales@newcanbio.com	China	9981	58
Wuhan Demeikai Biotechnology Co., Ltd	+8618942921723	info@dmksw.xin	China	717	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6391	58

Supplier	Advantage
ATK CHEMICAL COMPANY LIMITED	60
Jinan Carbotang Biotech Co.,Ltd.	58
Alchem Pharmtech,Inc.	58
Zhengzhou Alfa Chemical Co.,Ltd	58
TargetMol Chemicals Inc.	58
Shanghai UCHEM Inc.	58
Zhejiang J&C Biological Technology Co.,Limited	58
NewCan Biotech Limited	58
Wuhan Demeikai Biotechnology Co., Ltd	58
InvivoChem	58

Synthesis and Introduction of Maribavir
Maribavir is synthesised using 4,5-Dichloro-1,2-phenylenediamine as a raw material by chemical reaction.
Jan 9，2024

View Lastest Price from BENZIMIDAVIR manufacturers

Image	Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
	2024-11-19	Maribavir 176161-24-3	US $36.00-89.00 / mg		99.85%	10g	TargetMol Chemicals Inc.

Maribavir
176161-24-3
US $36.00-89.00 / mg
99.85%
TargetMol Chemicals Inc.

BENZIMIDAVIR Spectrum

BENZIMIDAVIR(176161-24-3)¹HNMR

176161-24-3(BENZIMIDAVIR)Related Search:

N,N-DIETHYLBENZAMIDE 1-PROPYL-1H-BENZOIMIDAZOL-2-YLAMINE 6-CHLORO-1H-BENZO[D]IMIDAZOL-2-AMINE 1-HYDROXYMETHYLBENZIMIDAZOLE 1H-Benzimidazol-2-amine,5-chloro-1-methyl-(9CI)

5,6-DICHLORO-2-ISOPROPYLAMINOBENZIMIDAZOLE 1,4-ANHYDRO-L-RIBITOL 5,6-DICHLORO-1H-BENZIMIDAZOL-2-AMINE BENZIMIDAVIR

1of2

5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine BW 1263W94 GW 257406X (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)t 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE BENZIMIDAVIR BENZIMIDAVIR, 5,6-DICHLORO-2-（ISOPROPYLAMINO）-1-(β-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE 5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE BENZIMIDAVIR: 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(SS-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetr 1263W94 1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl- Maribavi Maribavir Malibawei Malibave. Maribavir Impurity Crystal-Free Type VI 176161-24-3 76161-24-3 C15H19Cl2N3O4 Inhibitors